Asset Details
Do you wish to reserve the book?
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Do you wish to request the book?
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
2012
Overview
The combination of anastrozole and fulvestrant — which interfere with estrogen signaling by distinct mechanisms — increases progression-free and overall survival as compared with anastrozole alone or anastrozole followed by fulvestrant in women with HR-positive breast cancer.
Endocrine therapy plays a central role in the treatment of hormone-receptor (HR)–positive metastatic breast cancer.
1
Selective aromatase inhibitors, such as anastrozole, letrozole, and exemestane, lower the estrogen level and are used as first-line endocrine treatments of HR-positive metastatic disease, owing to their superiority over tamoxifen.
1
Fulvestrant (Faslodex, AstraZeneca) is an analogue of estradiol that down-regulates the estrogen receptor by disrupting estrogen-receptor dimerization and accelerating degradation of the unstable fulvestrant–estrogen-receptor complex.
2
This effect leads to reduced cross-talk between the estrogen receptor and estrogen-independent growth factor signaling, thus delaying resistance to hormone therapy.
2
Clinically, fulvestrant at a dose of 250 mg monthly . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Aromatase Inhibitors - administration & dosage
/ Aromatase Inhibitors - adverse effects
/ Biological and medical sciences
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - mortality
/ Breast Neoplasms - pathology
/ Estradiol - administration & dosage
/ Estradiol - analogs & derivatives
/ Estrogen Antagonists - administration & dosage
/ Estrogen Antagonists - adverse effects
/ Female
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Nitriles - administration & dosage
/ Patients
/ Survival
/ Triazoles - administration & dosage
/ Tumors
